DOI QR코드

DOI QR Code

A Case of Polycythemia Vera with a JAK2V617F Mutation Combined with Smoldering Myeloma

JAK2 돌연변이를 갖는 진성적혈구 증가증과 무증상 다발성 골수종이 동반된 1예

  • Jung, Yun Hwa (Department of Internal Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Woo, In Sook (Department of Internal Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Han, Sang Bong (Department of Laboratory Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Lee, Je Hoon (Department of Laboratory Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Han, Chi Wha (Department of Internal Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea College of Medicine)
  • 정윤화 (가톨릭대학교 의과대학 여의도성모병원 내과) ;
  • 우인숙 (가톨릭대학교 의과대학 여의도성모병원 내과) ;
  • 한상봉 (가톨릭대학교 의과대학 여의도성모병원 진단검사의학과) ;
  • 이제훈 (가톨릭대학교 의과대학 여의도성모병원 진단검사의학과) ;
  • 한치화 (가톨릭대학교 의과대학 여의도성모병원 내과)
  • Received : 2012.06.06
  • Accepted : 2012.09.07
  • Published : 2013.02.01

Abstract

The lymphoproliferative disease multiple myeloma and the myeloproliferative disease polycythemia vera have different pathogenic mechanisms and different natural courses. Thus, the concomitant development of these two diseases in the same individual is rare. In most previously reported cases of both diseases, one disease was assumed to be a secondary malignancy caused by chemotherapy for the other primary disease. Our case was diagnosed as smoldering myeloma based on increased bone marrow plasma cell numbers and monoclonal gammopathy during a regular follow-up visit for JAK2V617F mutation-positive polycythemia vera, which had not been treated except with phlebotomy. This case provides useful clues for understanding the pathogenesis of these two hematological malignancies and the association between them. Here, we report a case of polycythemia vera with a JAK2V617F mutation combined with smoldering myeloma and discuss the clinical significance and pathogenic association between these disorders of different lineages, along with a literature review.

저자들은 JAK2V617F 돌연변이를 동반한 진성적혈구증가증 환자에서 무증상 다발성골수종이 병발한 증례를 경험하였기에 문헌고찰과 함께 흥미로운 증례로 보고한다.

Keywords

References

  1. Rizzi R, Liso A, Pannunzio A, Carluccio P, Specchia G, Liso V. Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature. Leuk Lymphoma 2002;43:2217-2220. https://doi.org/10.1080/1042819021000016113
  2. Fink L, Bauer F, Perry JJ. Coincidental polycythemia vera and multiple myeloma: case report and review. Am J Hematol 1993;44:196-200. https://doi.org/10.1002/ajh.2830440311
  3. Saba NF, Warth JA, Ross DG. Simultaneous occurrence of polycythemia vera and Waldenstrom macroglobulinemia: a case report and review of the literature. Haematologia (Budap) 2002;32:17-23. https://doi.org/10.1163/156855902760262727
  4. Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol 2006;134: 366-384. https://doi.org/10.1111/j.1365-2141.2006.06206.x
  5. Fiorini A, Farina G, Reddiconto G, et al. Screening of JAK2 V617F mutation in multiple myeloma. Leukemia 2006; 20:1912-1913. https://doi.org/10.1038/sj.leu.2404332
  6. Kuroda J, Matsumoto Y, Tanaka R, et al. JAK2V617Fositive essential thrombocythemia and multiple myeloma with IGH/CCND1 gene translocation coexist, but originate from separate clones. Acta Haematol 2008;120:177-181. https://doi.org/10.1159/000187645
  7. Bommert K, Bargou RC, Stühmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006;42: 1574-1580. https://doi.org/10.1016/j.ejca.2005.12.026
  8. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-598. https://doi.org/10.1038/nrc2189